Skip to main content
Elsevier

Neurotoxicity of Drugs of Abuse

  • 1st Edition, Volume 8 - September 15, 2022
  • Latest edition
  • Editors: Lucio G. Costa, Michael Aschner, William Slikker Jr.
  • Language: English

Neurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxi… Read more

Description

Neurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxicity potential of several agents including marijuana, fentanyl, and ketamine are carefully reviewed, and their short-term and chronic effects are categorized. Pharmacokinetic profiles as well as mechanisms of action for these and other drugs of abuse such as alcohol and nicotine are also evaluated. The implications of short and long-term abuse for agents such as PCP are also characterized. The reader will come away with a fuller understanding of the adverse effects of drugs of abuse on the nervous system.

Key features

  • Describes in detail the characteristics of drugs of abuse that produce neurotoxicity
  • Summarizes both the short and long-term adverse effects of drugs of abuse on the nervous system
  • Describes potential mechanisms of action of centrally acting drugs of abuse

Readership

Basic researchers, clinicians, epidemiologists, regulators, drug developers, chemists

Table of contents

Preface
William Slikker, Jr.

1. Cannabinoids
G. Jean Harry

2. Converging mechanisms in ethanol neurotoxicity
Miriam Beatriz Virgolini and Ricardo Marcos Pautassi

3. Neurotoxicology of nicotine and tobacco
Edward D. Levin

4. The neurotoxic potential of opioids including fentanyl and fentanyl analogs
R. Daniel Mellon

5. Phencyclidine (PCP)-induced neurotoxicity and behavioral deficits
Cheng Wang, Shuliang Liu, Leah E. Latham, Fang Liu, Tucker A. Patterson and William Slikker Jr

6. The mysterious beauty of ketamine: benefits and risks
Donald R. Mattison, Abdallah Alami, Thomas J. Moore and G. Caleb Alexander

Product details

  • Edition: 1
  • Latest edition
  • Volume: 8
  • Published: October 7, 2022
  • Language: English

About the editors

Lucio G. Costa

Serial Volume Editor
Dr. Costa is Professor Emeritus of Toxicology in the Department of Environmental and Occupational Health Sciences at the University of Washington in Seattle. Before joining the University of Washington in 1983 he received a doctorate in Pharmacology from the University of Milano and was a postdoctoral fellow at the University of Texas at Houston. Over the years he served as the Director of the University of Washington Toxicology Program, Director of the Neurotoxicology Research Core of the NIEHS Center in Ecogenetics and Environmental Health, and a Core Faculty of the Environmental and Occupational Epidemiology Training Program and the Environmental Pathology/Toxicology Training Program at the University of Washington. He has also held professorial positions at various Universities in Italy (Parma, Bari, Roma, Pavia, Milano). He is a member of several national and international professional organizations, a Fellow of the Academy of Toxicological Sciences, and a European Certified Toxicologist. He received various awards for his scientific accomplishments, including the Achievement Award from the Society of Toxicology. Dr. Costa has been a member of several panels and committees at the national and international level dealing with toxicology and risk assessment issues. He has been teaching classes in pharmacology, toxicology, and neurotoxicology for over 35 years, and has kept an active research program in neurotoxicology, with >500 publications, books and book chapters. The primary focus of his research relates to the toxicology and neurotoxicology of pesticides, environmental contaminants, alcohol, air pollution, and on various aspects of gene-environment interactions in relationship to neurotoxicity and neurodegeneration.
Affiliations and expertise
Professor of Toxicology, University of Washington, Seattle, WA, USA

Michael Aschner

Serial Volume Editor
Dr. Aschner serves as the Harold and Muriel Block Chair in Molecular Pharmacology at Albert Einstein College of Medicine. He served on numerous toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control, FDA, National Academy of Sciences, US Department of Defense), and was a member and chair of the Neurotoxicology and Alcohol study section (NIH). He served as the President of the Society of Toxicology and has previously served as the President of the Academy of Toxicological Sciences and the International Neurotoxicology Association. He has authored (co-authored) >1,100 peer reviewed manuscripts and 110 book chapters, his h-index is 124, and he is a recipient of Honorary Doctorate from the University of Cordoba in Argentina. Research in his lab focuses on: (1) Modulation of C. elegans genes (aat, skn-1, daf-16) that are homologous to mammalian regulators of methylmercury (MeHg) uptake and cellular resistance will modify dopaminergic neurodegeneration in response to MeHg exposure. (2) Under conditions of MeHg-induced oxidative stress, Nrf2 (a master regulator of antioxidant responses) coordinates the upregulation of cytoprotective genes that combat MeHg-induced oxidative injury, and that genetic and biochemical changes that negatively impact upon Nrf2 function increase MeHg’s neurotoxicity. (3) PARK2, a strong PD genetic risk factor, alters neuronal vulnerability to modifiers of cellular Mn status, particularly at the level of mitochondrial dysfunction and oxidative stress. His studies are designed to (1) shed novel mechanistic insight into metal-induced neurodegeneration; (2) identify targets for genetic or pharmacologic modulation of neurodegenerative disorders; (3) increase knowledge of the pathway involved in oxidative stress; (4) develop improved research models for human disease using knowledge of environmental sciences.

Affiliations and expertise
Professor, Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA

William Slikker Jr.

Serial Volume Editor
Dr. William Slikker, Jr. was the director of FDA’s National Center for Toxicological Research (NCTR) before his retirement. He received his Ph.D. in pharmacology and toxicology from the University of California at Davis. Dr. Slikker holds adjunct professorships in the Department of Pediatrics, as well as the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences. He has held committee chairmanships or elected offices in several scientific societies including the Teratology Society (serving as president) and the American Society for Pharmacology and Experimental Therapeutics (chair, Developmental Pharmacology Section and member, Program Committee). Dr. Slikker is also the co-founder and past president of the MidSouth Computational Biology and Bioinformatics Society. He is currently associate editor for NeuroToxicology and associate editor for the “Environmental Health” section of Experimental Biology and Medicine. He is the past president of The Academy of Toxicological Sciences and the Society of Toxicology. He is a recipient of the 2014 George H. Scott Memorial Award from The Toxicology Forum and was invited to present the Warkany Lecture at the 2015 annual meeting of the Teratology Society. In early 2019, the Academy of Toxicological Sciences selected Dr. Slikker to receive the prestigious Mildred S. Christian Career Achievement Award. The Society for Birth Defects Research and Prevention selected Dr. Slikker to be the recipient of the 2022 Edward W. Carney Distinguished Service Award. Dr. Slikker has authored or co-authored over 380 publications in the areas of transplancentalpharmacokinetics, developmental neurotoxicology, neuroprotection, systems biology, and risk assessment. Dr. Slikker’s recent research has highlighted the concern for thousands of infants and toddlers who undergo longer-duration general anesthesia. He has performed research with his team and published over 25 peer-reviewed papers outlining the issue of brain-cell death and cognitive-function deficits in animal models that may result from several hours of anesthesia at a critical time of development. He has also, with the use of in vitro and in vivo techniques in rodents and nonhuman primates, defined possible mechanisms of toxicity and protective pathways to prevent the detrimental effects of general anesthesia. Through these and related scientific contributions, he has identified and characterized a host of minimally invasive biomarkers of neurotoxicity including the use of preclinical imaging (MRI, MicroPET/CT), genomic and lipidomic analysis, and modeling approaches to characterize and quantify adult and developmental neurotoxicity. He has also served on several national/international advisory panels for ILSI, HESI, CIIT, EPA, NIEHS, NAS, NIH and WHO.
Affiliations and expertise
National Center for Toxicological Research, Jefferson, US FDA, AR, USA

View book on ScienceDirect

Read Neurotoxicity of Drugs of Abuse on ScienceDirect